These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21339073)

  • 1. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
    Schutz FA; Je Y; Choueiri TK
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of dermatological toxicities associated with sorafenib.
    Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
    Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.
    Zhao B; Zhao H
    Oncotarget; 2017 Nov; 8(55):93813-93824. PubMed ID: 29212191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
    Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
    Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
    Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
    J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.
    Teo YL; Ho HK; Chan A
    Cancer Treat Rev; 2013 Apr; 39(2):199-206. PubMed ID: 23099278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.